SOPHION BIOSCIENCE A/S: Financial statements 2013
CVR: 10021065
Source: annual report 2013, Danish Business Authority
01/01/2013 – 31/12/2013
SOPHION BIOSCIENCE A/S (CVR 10021065) has filed annual accounts for 2013. In 2013, the company reported revenue of DKK 83,365,000 and a net result of DKK 18,327,000. The profit margin was 22%. Equity in the 2013 report amounted to DKK 105,825,000. The solvency ratio was 86.3%.
- Revenue
- DKK 83,365,000
- Gross Profit
- DKK 53,957,000
- Profit/Loss
- DKK 18,327,000
- Equity
- DKK 105,825,000
- Total Assets
- DKK 122,683,000
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2013
As of August 16, 2013, Morten Sunesen has joined the board of directors of SOPHION BIOSCIENCE A/S.
As of August 16, 2013, Torsten Freltoft has left the board of directors of SOPHION BIOSCIENCE A/S.
As of August 16, 2013, Morten Sunesen is registered as adm. dir. of SOPHION BIOSCIENCE A/S.
As of August 16, 2013, Torsten Freltoft has stepped down as adm. dir. of SOPHION BIOSCIENCE A/S.
SOPHION BIOSCIENCE A/S has published its annual report for 2012.
As of February 1, 2013, Anna Christina Rubenhag has joined the board of directors of SOPHION BIOSCIENCE A/S.
As of February 1, 2013, Johan Olof Tade von Heine has joined the board of directors of SOPHION BIOSCIENCE A/S.
As of February 1, 2013, Johan Olof Tade von Heijne has joined the board of directors of SOPHION BIOSCIENCE A/S.
As of February 1, 2013, Johan Olof Tade von Heine has left the board of directors of SOPHION BIOSCIENCE A/S.
As of February 1, 2013, Jan Tomas Wahlström has left the board of directors of SOPHION BIOSCIENCE A/S.
About SOPHION BIOSCIENCE A/S
SOPHION BIOSCIENCE A/S is a Danish company of the type Aktieselskab based in Ballerup, founded in 2000. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Michel Krall Jürgens. The board consists of Harald Høegh (chair), Eirik Lauglo, Gustaf Peter Reinhold von Ehrenheim and Peter Max. The company is owned by Sapphire Bioscience Holding ApS. The company has 41 employees (2018). In 2025, the company reported a gross profit of DKK 102,112,000 and a net result of DKK 4,354,000 compared with DKK 39,127,000 the year before. Equity in the 2025 report amounted to DKK 178,418,000.